Louis Bessette
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Louis Bessette has a total of 211 co-authors. Here are the top co-authors by number of shared publications:
- Carol A. Hitchon
Department of Internal Medicine, Max Rady College of Medicine, Rady Faculty of Health Sciences, University of Manitoba, Winnipeg, Canada
6 shared publications - Gilles Boire
Université de Sherbrooke, Sherbrooke, QC, Canada
6 shared publications - Glen Stewart Hazlewood
Department of Community Health Sciences, Cumming School of Medicine, University of Calgary, Calgary, Canada; Arthritis Research Canada, University of British Columbia, Vancouver, Canada; McCaig Institute for Bone and Joint Health, University of Calgary, Calgary, Canada
6 shared publications - Vivian P. Bykerk
V.P. Bykerk, MD, Hospital for Special Surgery, Division of Rheumatology, New York, NY, USA
6 shared publications - J. Carter Thorne
J.C. Thorne, MD, FRCPC, Assistant Past Professor, Department of Medicine, University of Toronto; Medical Director, The Arthritis Program; Board Chair Centre of Arthritis Excellence, Newmarket, Ontario, Canada
5 shared publications - Janet Elizabeth Pope
University of Western Ontario, London, Ontario, Canada
5 shared publications
Latest Publications
- 28 August 2026
- Published by Elsevier in Annals of the Rheumatic Diseases
- Vol. 85 (11) , 2129-2135
Use of parenteral compared with oral glucocorticoids in early rheumatoid arthritis for chance of being off steroids and escalation of therapy at 1 year
- 28 August 2026
- Published by Elsevier in Annals of the Rheumatic Diseases
- Vol. 85 (11) , 2129-2135
Use of parenteral compared with oral glucocorticoids in early rheumatoid arthritis for chance of being off steroids and escalation of therapy at 1 year
- Open Access
- 23 June 2026
- Published by Springer Nature in Advances in Rheumatology
- Vol. 66 (1)
CDAI trajectories in patients with rheumatoid arthritis treated with abatacept in real-world
Background: To describe the 12-month Clinical Disease Activity Index (CDAI) trajectory patterns and their determinants in patients with rheumatoid arthritis (RA) treated with subcutaneous abatacept. Methods: This was a post hoc analysis of adult patients with RA from the Abatacept Best Care (ABC) study. A growth mixture model (GMM) with Bayesian imputation for missing endpoints was used to define CDAI trajectory groups over 12 months. Determinants of trajectory patterns were identified among baseline patient and disease characteristics using bivariate comparisons and multivariable logistic regression with stepwise selection. Results: For the overall study sample ( n = 256) mean (SD) age was 60.1 (11.5) years, 191 (75%) were female, and baseline CDAI was 30.1 (10.6). The GMM identified 3 trajectory groups that were classified as Rapid Responders (RR; n = 125 [49%]), Late Responders (LR; n = 96 [38%]), and Non-Responders (NR; n = 35 [14%]). RR had lower baseline CDAI, Disease Activity Score 28 - C-Reactive Protein, Patient Global Assessment (PtGA), Routine Assessment of Patient Index Data 3, Simplified Disease Activity Index, and Tender Joint Count compared to LR and NR ( p < 0.001). Lower baseline PtGA, Rheumatic Disease Comorbidity Index, and lack of prior biologic use were significant predictors of RR ( p < 0.03). CDAI scores at 3 months were not predictive of 12-month response to treatment. Conclusions: Approximately 85% of the abatacept-treated patients with RA in this study showed Rapid or Late CDAI reduction over 12 months. Trajectory-based analyses are informative and may have implications for clinical practice and research. Trial registration: This study was registered on 06 September 2017 in ClinicalTrials.gov under the registration number NCT03274141.
- 23 June 2026
- Published by Springer Nature in Advances in Rheumatology
- Vol. 66 (1)
Open AccessCDAI trajectories in patients with rheumatoid arthritis treated with abatacept in real-world
Background: To describe the 12-month Clinical Disease Activity Index (CDAI) trajectory patterns and their determinants in patients with rheumatoid arthritis (RA) treated with subcutaneous abatacept. Methods: This was a post hoc analysis of adult patients with RA from the Abatacept Best Care (ABC) study. A growth mixture model (GMM) with Bayesian imputation for missing endpoints was used to define CDAI trajectory groups over 12 months. Determinants of trajectory patterns were identified among baseline patient and disease characteristics using bivariate comparisons and multivariable logistic regression with stepwise selection. Results: For the overall study sample ( n = 256) mean (SD) age was 60.1 (11.5) years, 191 (75%) were female, and baseline CDAI was 30.1 (10.6). The GMM identified 3 trajectory groups that were classified as Rapid Responders (RR; n = 125 [49%]), Late Responders (LR; n = 96 [38%]), and Non-Responders (NR; n = 35 [14%]). RR had lower baseline CDAI, Disease Activity Score 28 - C-Reactive Protein, Patient Global Assessment (PtGA), Routine Assessment of Patient Index Data 3, Simplified Disease Activity Index, and Tender Joint Count compared to LR and NR ( p < 0.001). Lower baseline PtGA, Rheumatic Disease Comorbidity Index, and lack of prior biologic use were significant predictors of RR ( p < 0.03). CDAI scores at 3 months were not predictive of 12-month response to treatment. Conclusions: Approximately 85% of the abatacept-treated patients with RA in this study showed Rapid or Late CDAI reduction over 12 months. Trajectory-based analyses are informative and may have implications for clinical practice and research. Trial registration: This study was registered on 06 September 2017 in ClinicalTrials.gov under the registration number NCT03274141.
- 15 January 2026
- Published by The Journal of Rheumatology in The Journal of Rheumatology
- Vol. 53 (9) , 971-976
Stressful Life Events in the Year Prior to Diagnosis and Associations With Rheumatoid Arthritis Characteristics at Presentation and 1 Year Later
Objective: To evaluate the relationship between major life stressors in the year prior to diagnosis and rheumatoid arthritis (RA) symptoms and function at diagnosis and at 1 year. Methods: Data were from adults with RA in the Canadian Early Arthritis Cohort, a multicenter inception cohort from January 2007 to March 2017 with ≥ 12 months of follow-up. Patients completed questionnaires about stressful life events in the prior year: Health Assessment Questionnaire–Disability Index (HAQ-DI); 12-item Short Form Health Survey; and 11-point rating scales of sleep, fatigue, pain, and patient global assessment (PtGA). Group characteristics were compared with ANOVA or chi-square test, and adjusted multivariable regression models examined the effect of stressors on symptoms and function at 1 year. Results: The 1933 participants were mostly White (87%) women (72%) with a mean age of 55 years; 52% reported ≥ 1 stressors in the year prior to diagnosis. Around diagnosis, patients reporting major stressors had significantly worse mean HAQ-DI, depression, sleep, fatigue, pain, and PtGA, which generally worsened with the type and number of stressors. At 1 year, the odds of depression and disability, and ratings of pain, fatigue, poor sleep, and PtGA generally increased with an increasing number of stressors, though Simplified Disease Activity Index (SDAI) improved similarly among groups. Conclusion: Fifty-two percent of patients with newly diagnosed RA reported stressful life events in the year prior to diagnosis that were associated with worse disability, depression, pain, fatigue, sleep, and well-being, but not SDAI, at diagnosis. Poorer patient-reported outcomes persisted at 1 year despite similar improvements in SDAI. Results highlight the potential independent contributions of environmental and psychological factors in the onset and course of RA.
- 15 January 2026
- Published by The Journal of Rheumatology in The Journal of Rheumatology
- Vol. 53 (9) , 971-976
Stressful Life Events in the Year Prior to Diagnosis and Associations With Rheumatoid Arthritis Characteristics at Presentation and 1 Year Later
Objective: To evaluate the relationship between major life stressors in the year prior to diagnosis and rheumatoid arthritis (RA) symptoms and function at diagnosis and at 1 year. Methods: Data were from adults with RA in the Canadian Early Arthritis Cohort, a multicenter inception cohort from January 2007 to March 2017 with ≥ 12 months of follow-up. Patients completed questionnaires about stressful life events in the prior year: Health Assessment Questionnaire–Disability Index (HAQ-DI); 12-item Short Form Health Survey; and 11-point rating scales of sleep, fatigue, pain, and patient global assessment (PtGA). Group characteristics were compared with ANOVA or chi-square test, and adjusted multivariable regression models examined the effect of stressors on symptoms and function at 1 year. Results: The 1933 participants were mostly White (87%) women (72%) with a mean age of 55 years; 52% reported ≥ 1 stressors in the year prior to diagnosis. Around diagnosis, patients reporting major stressors had significantly worse mean HAQ-DI, depression, sleep, fatigue, pain, and PtGA, which generally worsened with the type and number of stressors. At 1 year, the odds of depression and disability, and ratings of pain, fatigue, poor sleep, and PtGA generally increased with an increasing number of stressors, though Simplified Disease Activity Index (SDAI) improved similarly among groups. Conclusion: Fifty-two percent of patients with newly diagnosed RA reported stressful life events in the year prior to diagnosis that were associated with worse disability, depression, pain, fatigue, sleep, and well-being, but not SDAI, at diagnosis. Poorer patient-reported outcomes persisted at 1 year despite similar improvements in SDAI. Results highlight the potential independent contributions of environmental and psychological factors in the onset and course of RA.
- Open Access
- 19 September 2025
- Published by Springer Nature in Rheumatology and Therapy
- Vol. 12 (6) , 1043-1055
Safety of Golimumab in Patients with Rheumatoid Arthritis, Psoriatic Arthritis, and Axial Spondyloarthritis: Results from a Real-World Canadian Setting
Introduction This work aims to describe the risk of major adverse cardiovascular events (MACE), malignancy, and mortality in real-world patients with rheumatoid arthritis (RA), psoriatic arthritis (PsA), or axial spondyloarthritis (axSpA) treated with subcutaneous (SC) golimumab. Methods This post hoc analysis included patients treated with SC golimumab from the BioTRAC registry. Incidence rates (IR) per 100 patient-years (PYs) and time to onset of adverse events of special interest (AEoSI), including MACE, malignancies, mortality, serious AEs (SAEs), and serious infections (SIs), were assessed in subgroups based on age, sex, prior tumor necrosis factor inhibitor experience, smoking status, and baseline methotrexate and oral steroid use. All analyses were stratified by indication. Results Of 1231 patients included, 529 had RA, 281 had PsA, and 421 had axSpA. At baseline, mean patient age was 57.7, 52.8, and 45.7 years in the RA, PsA, and axSpA groups, respectively. Most patients with RA (76.2%) and PsA (53.7%); 40.9% of patients with axSpA were female. The IR (95% confidence interval) for MACE was 1.1 (0.6, 2.0) events/100 PYs in the RA group with no events in the PsA and axSpA groups. Malignancy IRs were 1.4 (0.8, 2.3), 0.4 (0.0, 1.3), and 1.0 (0.4, 2.1)/100 PYs. SAE incidence ranged from 7.6 (5.5, 10.3)/100 PYs in the PsA group to 11.4 (9.4, 13.6) in the RA group, and that of SIs from 1.3 (0.5, 2.7)/100 PYs in patients with PsA to 2.3 (1.4, 3.4) in patients with RA. IRs for mortality were 0.7 (0.3, 1.4; n = 7), 0.2 (0.0, 1.0; n = 1), and 0.3 (0.0, 1.1; n = 2)/100 PYs in RA, PsA, and axSpA, respectively. Older patients with RA had a significantly shorter time to MACE (p = 0.007). Conclusions Patients with RA, PsA, and axSpA treated with SC golimumab in the real world had a low incidence of MACE, malignancy, and all-cause mortality, further confirming the safety of golimumab for the treatment of rheumatic diseases. Trial Registration Number and Date ClinicalTrials.gov identifier, NCT00741793, August 22, 2008.
- 19 September 2025
- Published by Springer Nature in Rheumatology and Therapy
- Vol. 12 (6) , 1043-1055
Open AccessSafety of Golimumab in Patients with Rheumatoid Arthritis, Psoriatic Arthritis, and Axial Spondyloarthritis: Results from a Real-World Canadian Setting
Introduction This work aims to describe the risk of major adverse cardiovascular events (MACE), malignancy, and mortality in real-world patients with rheumatoid arthritis (RA), psoriatic arthritis (PsA), or axial spondyloarthritis (axSpA) treated with subcutaneous (SC) golimumab. Methods This post hoc analysis included patients treated with SC golimumab from the BioTRAC registry. Incidence rates (IR) per 100 patient-years (PYs) and time to onset of adverse events of special interest (AEoSI), including MACE, malignancies, mortality, serious AEs (SAEs), and serious infections (SIs), were assessed in subgroups based on age, sex, prior tumor necrosis factor inhibitor experience, smoking status, and baseline methotrexate and oral steroid use. All analyses were stratified by indication. Results Of 1231 patients included, 529 had RA, 281 had PsA, and 421 had axSpA. At baseline, mean patient age was 57.7, 52.8, and 45.7 years in the RA, PsA, and axSpA groups, respectively. Most patients with RA (76.2%) and PsA (53.7%); 40.9% of patients with axSpA were female. The IR (95% confidence interval) for MACE was 1.1 (0.6, 2.0) events/100 PYs in the RA group with no events in the PsA and axSpA groups. Malignancy IRs were 1.4 (0.8, 2.3), 0.4 (0.0, 1.3), and 1.0 (0.4, 2.1)/100 PYs. SAE incidence ranged from 7.6 (5.5, 10.3)/100 PYs in the PsA group to 11.4 (9.4, 13.6) in the RA group, and that of SIs from 1.3 (0.5, 2.7)/100 PYs in patients with PsA to 2.3 (1.4, 3.4) in patients with RA. IRs for mortality were 0.7 (0.3, 1.4; n = 7), 0.2 (0.0, 1.0; n = 1), and 0.3 (0.0, 1.1; n = 2)/100 PYs in RA, PsA, and axSpA, respectively. Older patients with RA had a significantly shorter time to MACE (p = 0.007). Conclusions Patients with RA, PsA, and axSpA treated with SC golimumab in the real world had a low incidence of MACE, malignancy, and all-cause mortality, further confirming the safety of golimumab for the treatment of rheumatic diseases. Trial Registration Number and Date ClinicalTrials.gov identifier, NCT00741793, August 22, 2008.
- Open Access
- 13 September 2025
- Published by Oxford University Press (OUP) in Rheumatology Advances in Practice
- Vol. 9 (4) , rkaf120
Predictors of depression trajectories during the COVID-19 pandemic in adults with rheumatoid arthritis: results from the Canadian Early Arthritis Cohort
Objectives: Growing evidence points to mental health impacts of coronavirus disease 2019 (COVID-19). We explored trajectories of depressive symptoms in the year pre- and 2 years post-pandemic onset in adults with RA. Methods: Data are from the Canadian Early Arthritis Cohort (CATCH), a prospective, multicentre, early RA cohort of Canadian adults treated by rheumatologists. Pre-pandemic, participants completed patient-reported outcome measures and rheumatology exams in person. After March 2020, patient-reported outcomes were collected at in-person and virtual visits. We used group-based trajectory modelling to explore longitudinal patterns of depressive symptoms prior to and throughout the COVID-19 pandemic and multinomial regression to identify factors associated with depression trajectory group. Results: A total of 989 participants had a mean age of 60 years (s.d. 14), RA for 6 years (s.d. 4) and were mostly white (84%) and female (73%) with some college education (60%). Most (77%) were in Clinical Disease Activity Index remission/low disease activity prior to the pandemic. We identified four trajectories: resilient (no symptoms throughout: 60%), worsening (none–mild: 22%), improving (mild–minimal: 8%) and persistent (moderate–severe throughout: 9%). Age, sex, race, education, pain, physical and social functioning, fibromyalgia and history of anxiety/depression were associated with different trajectories. Conclusion: Although 60% had a consistent affect during the first 2 years of the pandemic, mood worsened in greater than one in five, suggesting a cumulative impact over time. Biological, psychological and social factors and worse pre-pandemic symptoms and function were associated with a greater risk of depression during the pandemic. Identifying at-risk groups impacted by major stressors like the pandemic may offer new opportunities to personalize treatment, allocate resources, reduce disease flares and improve outcomes.
- 13 September 2025
- Published by Oxford University Press (OUP) in Rheumatology Advances in Practice
- Vol. 9 (4) , rkaf120
Open AccessPredictors of depression trajectories during the COVID-19 pandemic in adults with rheumatoid arthritis: results from the Canadian Early Arthritis Cohort
Objectives: Growing evidence points to mental health impacts of coronavirus disease 2019 (COVID-19). We explored trajectories of depressive symptoms in the year pre- and 2 years post-pandemic onset in adults with RA. Methods: Data are from the Canadian Early Arthritis Cohort (CATCH), a prospective, multicentre, early RA cohort of Canadian adults treated by rheumatologists. Pre-pandemic, participants completed patient-reported outcome measures and rheumatology exams in person. After March 2020, patient-reported outcomes were collected at in-person and virtual visits. We used group-based trajectory modelling to explore longitudinal patterns of depressive symptoms prior to and throughout the COVID-19 pandemic and multinomial regression to identify factors associated with depression trajectory group. Results: A total of 989 participants had a mean age of 60 years (s.d. 14), RA for 6 years (s.d. 4) and were mostly white (84%) and female (73%) with some college education (60%). Most (77%) were in Clinical Disease Activity Index remission/low disease activity prior to the pandemic. We identified four trajectories: resilient (no symptoms throughout: 60%), worsening (none–mild: 22%), improving (mild–minimal: 8%) and persistent (moderate–severe throughout: 9%). Age, sex, race, education, pain, physical and social functioning, fibromyalgia and history of anxiety/depression were associated with different trajectories. Conclusion: Although 60% had a consistent affect during the first 2 years of the pandemic, mood worsened in greater than one in five, suggesting a cumulative impact over time. Biological, psychological and social factors and worse pre-pandemic symptoms and function were associated with a greater risk of depression during the pandemic. Identifying at-risk groups impacted by major stressors like the pandemic may offer new opportunities to personalize treatment, allocate resources, reduce disease flares and improve outcomes.
- 8 February 2025
- Published by Springer Nature in Rheumatology International
- Vol. 45 (3) , 1-9
The association between polypharmacy and disease control in rheumatoid arthritis and systemic lupus erythematosus: a cohort study
Polypharmacy can be associated with poor outcomes in chronic diseases. Our objective is to determine the prevalence of polypharmacy and its association with disease control in patients with rheumatoid arthritis (RA) and systemic lupus erythematosus (SLE). An observational study was conducted using the SARD database of the CHU de Québec. Participants newly diagnosed with RA or SLE enrolled in the database after 24 months were included. Collected data included number and type of medications, Charlson Comorbidity Index, and medication adherence (proportion of days covered during the first 180 days). Polypharmacy was defined as the simultaneous use ≥5 medications. Multivariable logistic and linear regressions were used to determine the association between polypharmacy and disease control (DAS28CRP, SLEDAI-2 K). The study included 111 participants (RA = 81; SLE = 30). Medication count increased at two years in RA (mean ± SD): 4.6 ± 3.3 to 6.9 ± 3.6; and SLE: 6.5 ± 4.6 to 7.80 ± 4.82. Polypharmacy prevalence increased at two years: RA: from 43 to 74%; SLE: from 47 to 73%. Mean medication adherence exceeded 85%. For RA participants, polypharmacy was associated with a better DAS28CRP score at one year [adjusted odds ratio of achieving a poor outcome: 0.17 (95%CI 0.04–0.71)], but this association was lost at two years [2.88 (0.45–18.29)]. For SLE, polypharmacy was not associated with disease activity based on the SLEDAI-2 K at one year [7.36 (0.26-211.16)] or two years [0.32 (0.05–1.99)]. Overall, polypharmacy is very prevalent in RA and SLE and could be positively associated with the level of disease control in the year after a diagnosis of RA.
- 8 February 2025
- Published by Springer Nature in Rheumatology International
- Vol. 45 (3) , 1-9
The association between polypharmacy and disease control in rheumatoid arthritis and systemic lupus erythematosus: a cohort study
Polypharmacy can be associated with poor outcomes in chronic diseases. Our objective is to determine the prevalence of polypharmacy and its association with disease control in patients with rheumatoid arthritis (RA) and systemic lupus erythematosus (SLE). An observational study was conducted using the SARD database of the CHU de Québec. Participants newly diagnosed with RA or SLE enrolled in the database after 24 months were included. Collected data included number and type of medications, Charlson Comorbidity Index, and medication adherence (proportion of days covered during the first 180 days). Polypharmacy was defined as the simultaneous use ≥5 medications. Multivariable logistic and linear regressions were used to determine the association between polypharmacy and disease control (DAS28CRP, SLEDAI-2 K). The study included 111 participants (RA = 81; SLE = 30). Medication count increased at two years in RA (mean ± SD): 4.6 ± 3.3 to 6.9 ± 3.6; and SLE: 6.5 ± 4.6 to 7.80 ± 4.82. Polypharmacy prevalence increased at two years: RA: from 43 to 74%; SLE: from 47 to 73%. Mean medication adherence exceeded 85%. For RA participants, polypharmacy was associated with a better DAS28CRP score at one year [adjusted odds ratio of achieving a poor outcome: 0.17 (95%CI 0.04–0.71)], but this association was lost at two years [2.88 (0.45–18.29)]. For SLE, polypharmacy was not associated with disease activity based on the SLEDAI-2 K at one year [7.36 (0.26-211.16)] or two years [0.32 (0.05–1.99)]. Overall, polypharmacy is very prevalent in RA and SLE and could be positively associated with the level of disease control in the year after a diagnosis of RA.
- Open Access
- 4 September 2024
- Published by Wiley in Arthritis Care & Research
- Vol. 76 (12) , 1626-1636
Barriers to, Facilitators of, and Interventions to Support Treat‐to‐Target Implementation in Rheumatoid Arthritis: A Systematic Review
Objective: Treat‐to‐target is recommended in the management of rheumatoid arthritis (RA) but its implementation is suboptimal. We aimed to identify interventional strategies targeted at improving treat‐to‐target implementation in RA by systematically reviewing published evidence on barriers to, facilitators of, and interventions to support treat‐to‐target implementation.Methods: Systematic and scoping literature searches in PubMed/MEDLINE, BIOSIS Previews, Derwent Drug File, Embase, EMCare, International Pharmaceutical Abstracts, and SciSearch were conducted to identify barriers/facilitators and interventions relating to treat‐to‐target implementation in RA. The quality of included studies was assessed using Critical Appraisal Skills Programme (CASP) checklists. Data related to barriers/facilitators and interventions were extracted, grouped, and summarized descriptively, and a narrative synthesis was generated.Results: In total, 146 articles were analyzed, of which 123 (84%) included ≥50% of the items assessed by CASP checklists. Of the 146 studies, 76 evaluated treat‐to‐target barriers and facilitators, from which 329 relevant statements were identified and regrouped into 18 target areas, including health care professional (HCP) or patient knowledge or perceptions; patient‐HCP communication or alignment; and time or resources. Overall, 56 interventions were identified from 70 studies across the 18 target areas; 54% addressed disease activity or patient‐reported outcome assessments. Of the 56 interventions identified, 36 improved treat‐to‐target implementation and/or patient outcomes in RA.Conclusion: Despite long‐established treat‐to‐target recommendations, there remain many barriers to its implementation. Interventions to improve treat‐to‐target should be developed further and assessed, with a particular focus on tailoring them to individual countries, regions, and health care settings.
- 4 September 2024
- Published by Wiley in Arthritis Care & Research
- Vol. 76 (12) , 1626-1636
Open AccessBarriers to, Facilitators of, and Interventions to Support Treat‐to‐Target Implementation in Rheumatoid Arthritis: A Systematic Review
Objective: Treat‐to‐target is recommended in the management of rheumatoid arthritis (RA) but its implementation is suboptimal. We aimed to identify interventional strategies targeted at improving treat‐to‐target implementation in RA by systematically reviewing published evidence on barriers to, facilitators of, and interventions to support treat‐to‐target implementation.Methods: Systematic and scoping literature searches in PubMed/MEDLINE, BIOSIS Previews, Derwent Drug File, Embase, EMCare, International Pharmaceutical Abstracts, and SciSearch were conducted to identify barriers/facilitators and interventions relating to treat‐to‐target implementation in RA. The quality of included studies was assessed using Critical Appraisal Skills Programme (CASP) checklists. Data related to barriers/facilitators and interventions were extracted, grouped, and summarized descriptively, and a narrative synthesis was generated.Results: In total, 146 articles were analyzed, of which 123 (84%) included ≥50% of the items assessed by CASP checklists. Of the 146 studies, 76 evaluated treat‐to‐target barriers and facilitators, from which 329 relevant statements were identified and regrouped into 18 target areas, including health care professional (HCP) or patient knowledge or perceptions; patient‐HCP communication or alignment; and time or resources. Overall, 56 interventions were identified from 70 studies across the 18 target areas; 54% addressed disease activity or patient‐reported outcome assessments. Of the 56 interventions identified, 36 improved treat‐to‐target implementation and/or patient outcomes in RA.Conclusion: Despite long‐established treat‐to‐target recommendations, there remain many barriers to its implementation. Interventions to improve treat‐to‐target should be developed further and assessed, with a particular focus on tailoring them to individual countries, regions, and health care settings.
- Open Access
- 6 August 2024
- Published by Springer Nature in Advances in Rheumatology
- Vol. 64 (1) , 1-10
Characteristics of patients with difficult-to-treat rheumatoid arthritis: a descriptive retrospective cohort study
Background: In 2021, an EULAR task force published a definition of difficult-to-treat rheumatoid arthritis (D2T RA). Our current knowledge of D2T RA with the EULAR definition is based on European and Asian cohorts, and no North American cohort has yet to be published. The aim of this study was to compare D2T RA patients to non-D2T RA who are good responders to advanced therapy, and to describe their evolution in an university health center patient cohort. Methods: This is a retrospective single centre study of the medical records of all adults with RA on at least one biologic or target synthetic DMARD (b/tsDMARD). D2T RA group was defined according to the EULAR definition of D2T RA. The non-D2T RA group was defined as a b/tsDMARD good responder who had low-disease activity or remission for at least one year on 1 or 2 b/tsDMARD mechanism of action. We compared the patients’ comorbidities, and history of b/tsDMARD use. Descriptive statistics and proportions were calculated. Kaplan-Meier analysis with log-rank test was used to estimate and compare median survival. Results: Among the 417 patients, 101 (24%) were D2T RA and 316 (76%) were non-D2T RA. D2T RA group was slightly younger (63 ± 9 years versus 65 ± 12 years, p = 0.045), more likely to have concomitant non-inflammatory pain (28% versus 8%, p < 0.0001) and to discontinue at least one b/tsDMARD due to intolerance (39% versus 10%, p < 0.0001). In the D2T RA group, JAK inhibitors were associated with longer drug continuation when used as the third b/tsDMARD. Fewer patients were using corticosteroid at their most recent follow-up in this Canadian cohort compared to others (16% versus from 29 to 74%). Conclusion: Concomitant non-inflammatory pain was more prevalent in D2T RA patients compared to b/tsDMARD good responder non-D2T RA patients. Steroid-sparing strategies is possible even in D2T RA patients. Future prospective research may compare JAK inhibitors with other mechanisms of action in D2T RA.
- 6 August 2024
- Published by Springer Nature in Advances in Rheumatology
- Vol. 64 (1) , 1-10
Open AccessCharacteristics of patients with difficult-to-treat rheumatoid arthritis: a descriptive retrospective cohort study
Background: In 2021, an EULAR task force published a definition of difficult-to-treat rheumatoid arthritis (D2T RA). Our current knowledge of D2T RA with the EULAR definition is based on European and Asian cohorts, and no North American cohort has yet to be published. The aim of this study was to compare D2T RA patients to non-D2T RA who are good responders to advanced therapy, and to describe their evolution in an university health center patient cohort. Methods: This is a retrospective single centre study of the medical records of all adults with RA on at least one biologic or target synthetic DMARD (b/tsDMARD). D2T RA group was defined according to the EULAR definition of D2T RA. The non-D2T RA group was defined as a b/tsDMARD good responder who had low-disease activity or remission for at least one year on 1 or 2 b/tsDMARD mechanism of action. We compared the patients’ comorbidities, and history of b/tsDMARD use. Descriptive statistics and proportions were calculated. Kaplan-Meier analysis with log-rank test was used to estimate and compare median survival. Results: Among the 417 patients, 101 (24%) were D2T RA and 316 (76%) were non-D2T RA. D2T RA group was slightly younger (63 ± 9 years versus 65 ± 12 years, p = 0.045), more likely to have concomitant non-inflammatory pain (28% versus 8%, p < 0.0001) and to discontinue at least one b/tsDMARD due to intolerance (39% versus 10%, p < 0.0001). In the D2T RA group, JAK inhibitors were associated with longer drug continuation when used as the third b/tsDMARD. Fewer patients were using corticosteroid at their most recent follow-up in this Canadian cohort compared to others (16% versus from 29 to 74%). Conclusion: Concomitant non-inflammatory pain was more prevalent in D2T RA patients compared to b/tsDMARD good responder non-D2T RA patients. Steroid-sparing strategies is possible even in D2T RA patients. Future prospective research may compare JAK inhibitors with other mechanisms of action in D2T RA.
- Open Access
Early clinical response associates with long-term outcomes with ixekizumab in radiographic axial spondyloarthritis
Background The Assessment of SpondyloArthritis international Society-European Alliance of Associations for Rheumatology recommendations for axial spondyloarthritis (axSpA) management include patient assessment for biological disease-modifying antirheumatic drug (bDMARD) treatment response after at least 12 weeks of treatment. The current treat-to-target strategy for axSpA is to achieve inactive disease (ID; Axial Spondyloarthritis Disease Activity Score (ASDAS) Methods This post hoc analysis included patients randomly assigned to IXE 80 mg every 4 weeks from COAST-V (NCT02696785), a phase 3 trial in bDMARD-naïve patients with r-axSpA. The proportion of patients who achieved ASDASResults Amongst 81 patients, 47 (58.0%) achieved ASDAS CII at week 12, with 70.2% (n=33) achieving ASDASConclusion This analysis reinforces the current recommendation that continuing treatment in those achieving ASDAS CII at week 12 and/or week 24 increases the likelihood of obtaining ID/LDA at week 52. Trial registration number NCT02696785.
Open AccessEarly clinical response associates with long-term outcomes with ixekizumab in radiographic axial spondyloarthritis
Background The Assessment of SpondyloArthritis international Society-European Alliance of Associations for Rheumatology recommendations for axial spondyloarthritis (axSpA) management include patient assessment for biological disease-modifying antirheumatic drug (bDMARD) treatment response after at least 12 weeks of treatment. The current treat-to-target strategy for axSpA is to achieve inactive disease (ID; Axial Spondyloarthritis Disease Activity Score (ASDAS) Methods This post hoc analysis included patients randomly assigned to IXE 80 mg every 4 weeks from COAST-V (NCT02696785), a phase 3 trial in bDMARD-naïve patients with r-axSpA. The proportion of patients who achieved ASDASResults Amongst 81 patients, 47 (58.0%) achieved ASDAS CII at week 12, with 70.2% (n=33) achieving ASDASConclusion This analysis reinforces the current recommendation that continuing treatment in those achieving ASDAS CII at week 12 and/or week 24 increases the likelihood of obtaining ID/LDA at week 52. Trial registration number NCT02696785.
- Open Access
- 11 March 2024
- Published by Springer Nature in Rheumatology and Therapy
- Vol. 11 (3) , 563-582
Real-World Effectiveness of Upadacitinib for Treatment of Rheumatoid Arthritis in Canadian Patients: Interim Results from the Prospective Observational CLOSE-UP Study
Introduction Upadacitinib (UPA), a selective, reversible, oral Janus kinase (JAK)-1 inhibitor, was approved in 2019 in Canada for the treatment of adults with moderately to severely active rheumatoid arthritis (RA). This phase 4 prospective study aimed to characterise the effectiveness of UPA in the real-world population of patients with RA. Methods Adults with RA who initiated treatment with once daily UPA (15 mg) and enrolled in the Canadian Real-Life post-marketing Observational Study assessing the Effectiveness of UPadacitinib for treating rheumatoid arthritis (CLOSE-UP) and who completed a 6-month assessment as of 28 February 2023 were included. The primary endpoint of the CLOSE-UP study is the proportion of patients achieving a Disease Activity Score-28 Joint Count C-reactive protein (DAS28-CRP) < 2.6 at 6 months. Data was collected at routine visits. Data analysed and summarised descriptively for the overall interim population and for subgroups based on prior therapy included remission or low disease activity, patient-reported outcomes (PROs), and adverse events. Results A total of 392 patients were included in the interim analysis. Overall, 63.5% (191/301) of patients achieved a DAS28-CRP score < 2.6 at month 6, with similar rates observed for all subgroups analysed according to prior therapy including those with prior JAK inhibitor exposure (range 57.4–71.0%), and in patients who received UPA monotherapy (71.6% [48/67]). Early (month 3) and sustained improvements up to 6 months were observed for all PROs. The safety profile was consistent with previous reports. Conclusion Real-world improvements in disease activity and PROs in response to UPA treatment were consistent with clinical trial data across a range of Canadian patients with prior therapy exposure and with UPA monotherapy, with an overall favourable benefit–risk profile. Trial Registration NCT04574492.
- 11 March 2024
- Published by Springer Nature in Rheumatology and Therapy
- Vol. 11 (3) , 563-582
Open AccessReal-World Effectiveness of Upadacitinib for Treatment of Rheumatoid Arthritis in Canadian Patients: Interim Results from the Prospective Observational CLOSE-UP Study
Introduction Upadacitinib (UPA), a selective, reversible, oral Janus kinase (JAK)-1 inhibitor, was approved in 2019 in Canada for the treatment of adults with moderately to severely active rheumatoid arthritis (RA). This phase 4 prospective study aimed to characterise the effectiveness of UPA in the real-world population of patients with RA. Methods Adults with RA who initiated treatment with once daily UPA (15 mg) and enrolled in the Canadian Real-Life post-marketing Observational Study assessing the Effectiveness of UPadacitinib for treating rheumatoid arthritis (CLOSE-UP) and who completed a 6-month assessment as of 28 February 2023 were included. The primary endpoint of the CLOSE-UP study is the proportion of patients achieving a Disease Activity Score-28 Joint Count C-reactive protein (DAS28-CRP) < 2.6 at 6 months. Data was collected at routine visits. Data analysed and summarised descriptively for the overall interim population and for subgroups based on prior therapy included remission or low disease activity, patient-reported outcomes (PROs), and adverse events. Results A total of 392 patients were included in the interim analysis. Overall, 63.5% (191/301) of patients achieved a DAS28-CRP score < 2.6 at month 6, with similar rates observed for all subgroups analysed according to prior therapy including those with prior JAK inhibitor exposure (range 57.4–71.0%), and in patients who received UPA monotherapy (71.6% [48/67]). Early (month 3) and sustained improvements up to 6 months were observed for all PROs. The safety profile was consistent with previous reports. Conclusion Real-world improvements in disease activity and PROs in response to UPA treatment were consistent with clinical trial data across a range of Canadian patients with prior therapy exposure and with UPA monotherapy, with an overall favourable benefit–risk profile. Trial Registration NCT04574492.